Study of Safety of RVL-1201 in Treatment of Blepharoptosis
Status:
Completed
Trial end date:
2019-03-27
Target enrollment:
Participant gender:
Summary
Phase 3 study to evaluate the extended safety of RVL-1201 compared to placebo for treatment
of blepharoptosis. Eligible subjects will be randomized to one of 2 treatment arms.